Breast Cancer in BRCA1/2 Mutation Carriers – Do We Treat It Differently? Focus on Systemic Therapy for BRCA1/2 Associated Breast Cancer


Klin Onkol 2019; 32(Suppl 2): 24-30. DOI: 10.14735/amko2019S24.

Hereditary breast cancer syndrome is associated with a higher risk of developing breast cancer and accounts for 5–10% of all breast tumors. Is it possible that mutations in BRCA1/2 genes (which are involved in DNA repair genes) should be treated differently from sporadic breast cancer? In addition to anthracyclines, taxanes are effective against tumors with a BRCA2 mutation. A TNT trial showed that platinum derivatives have marked effects against metastatic breast cancer. Data from neoadjuvant trials testing efficacy in triple negative cancer confirm that neoadjuvant chemotherapy is more effective against sporadic tumors, whereas the effect of carboplatin is not statistically significant, as opposed to sporadic cancer. A new group of therapeutics, particularly for tumors with mutations in BRCA1/2 genes, is PARP inhibitors. These treatments were effective not only against triple negative tumors but also against luminal tumors.

Full text in PDF